Zydus Cadila gets approval from Mexican authority to test COVID-19 drug

TIL Desk/Business/New Delhi/ Drug firm Zydus Cadila on Monday said it has received approval from Mexico’s regulatory authority Cofepris to test one of its lead research candidate Desidustat in the management of COVID-19.

“Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sant Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,” Cadila Healthcare said in a regulatory filing.

The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients.

“As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial,” the company added.